Associated Genetic Biomarkers
RECQL4 Loss is present in 0.06% of AACR GENIE cases, with anaplastic astrocytoma, colon adenocarcinoma, endometrial serous adenocarcinoma, hepatocellular carcinoma, and uterine corpus leiomyosarcoma having the greatest prevalence .
RECQL4 Loss serves as an inclusion eligibility criterion in 2 clinical trials, of which 1 is open and 1 is closed. Of the trials that contain RECQL4 Loss as an inclusion criterion, 2 are phase 2 (1 open).
Trials with RECQL4 Loss in the inclusion eligibility criteria most commonly target small cell lung carcinoma and urothelial carcinoma .
Olaparib is the most frequent therapy in trials with RECQL4 Loss as an inclusion criteria .
Significance of RECQL4 Loss in Diseases
Small Cell Lung Carcinoma +
RECQL4 is altered in 5.25% of small cell lung carcinoma patients .
RECQL4 Loss is an inclusion criterion in 1 clinical trial for small cell lung carcinoma, of which 0 are open and 1 is closed. Of the trial that contains RECQL4 Loss and small cell lung carcinoma as inclusion criteria, 1 is phase 2 (0 open) .
Urothelial Carcinoma +
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. Liu X, Wu C, Li C, and Boerwinkle E. dbNSFP v3.0: A one-stop database of functional predictions and annotations for human nonsynonymous and splice site SNVs. Human Mutation. 2015;37:235-241.
Liu X, Jian X, and Boerwinkle E. dbNSFP: A lightweight database of human nonsynonymous SNPs and their functional predictions. Human Mutation. 2011;32:894-899.
4. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.